DNA Hypermethylation Assay Confirms Negative Prostate Cancer Biopsy Results
|
By LabMedica International staff writers Posted on 10 Jun 2014 |

Image: ConfirmMDx detects an epigenetic field effect or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This epigenetic “halo” around a cancer lesion can be present despite having a normal appearance under the microscope (Photo courtesy of MDxHealth).
A commercially available assay that measures the level of hypermethylated DNA in tissue samples was found to accurately identify negative-for-cancer prostate tissues in more than 88% of cases.
Approximately 700,000 men in the USA receive a negative prostate biopsy result; however approximately 25% of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10–12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. The MDxHealth (Herstal, Belgium) "ConfirmMDx for Prostate Cancer" assay addresses the unmet medical need for a clinically effective diagnostic test to address this dilemma. "ConfirmMDx for Prostate Cancer" is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. The test helps urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule-in high risk patients who may require repeat biopsies and potential treatment.
In a study to validate the use of the MDxHealth assay, investigators at Johns Hopkins University (Baltimore, MD, USA) evaluated archived negative-for-cancer prostate biopsy core tissue samples from 350 subjects from five urologic centers in the USA. All subjects underwent a repeat biopsy within 24 months with a negative (controls) or positive (cases) histopathological result. The MDxHealth assay profiled methylation levels for the known tumor suppressor genes GSTP1, APC, and RASSF1, which are silenced by hypermethylation and fail to block cancer development.
Results of analysis of the two biopsy specimens from each patient showed that average levels of APC and RASSF1 were about twice as high in the 92 subjects whose second biopsies yielded positive results, as compared to the 228 with two negative biopsies. For GSTP1, the levels were more than eight times higher in the cancerous biopsies.
“Overall, if there is an absence of methylation in all three biomarkers, there is an 88% likelihood you do not have cancer,” said senior author Dr. Jonathan Epstein, professor of pathology, urology, and oncology at Johns Hopkins University. “The test is not 100% of an assurance, but it is a major step forward.”
“Often, one biopsy is not enough to definitively rule out prostate cancer,” said Dr. Epstein. “Our research finds that by looking for the presence or absence of cancer in a different way, we may be able to offer many men peace of mind without putting them through the pain, bleeding and risk of infection that can come with a repeat biopsy. It turns out as many as 20% of men have prostate cancer, even if their first biopsy results are negative. Approximately 40% of men with a negative biopsy go on to receive a second biopsy. Many high-risk men fear sampling errors in their initial biopsy, which often leads to a high rate of follow-up procedures to merely confirm the absence of the disease.”
The study was published in the April 16, 2014, online edition of the Journal of Urology.
Related Links:
MDxHealth
Johns Hopkins University
Approximately 700,000 men in the USA receive a negative prostate biopsy result; however approximately 25% of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10–12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. The MDxHealth (Herstal, Belgium) "ConfirmMDx for Prostate Cancer" assay addresses the unmet medical need for a clinically effective diagnostic test to address this dilemma. "ConfirmMDx for Prostate Cancer" is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. The test helps urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule-in high risk patients who may require repeat biopsies and potential treatment.
In a study to validate the use of the MDxHealth assay, investigators at Johns Hopkins University (Baltimore, MD, USA) evaluated archived negative-for-cancer prostate biopsy core tissue samples from 350 subjects from five urologic centers in the USA. All subjects underwent a repeat biopsy within 24 months with a negative (controls) or positive (cases) histopathological result. The MDxHealth assay profiled methylation levels for the known tumor suppressor genes GSTP1, APC, and RASSF1, which are silenced by hypermethylation and fail to block cancer development.
Results of analysis of the two biopsy specimens from each patient showed that average levels of APC and RASSF1 were about twice as high in the 92 subjects whose second biopsies yielded positive results, as compared to the 228 with two negative biopsies. For GSTP1, the levels were more than eight times higher in the cancerous biopsies.
“Overall, if there is an absence of methylation in all three biomarkers, there is an 88% likelihood you do not have cancer,” said senior author Dr. Jonathan Epstein, professor of pathology, urology, and oncology at Johns Hopkins University. “The test is not 100% of an assurance, but it is a major step forward.”
“Often, one biopsy is not enough to definitively rule out prostate cancer,” said Dr. Epstein. “Our research finds that by looking for the presence or absence of cancer in a different way, we may be able to offer many men peace of mind without putting them through the pain, bleeding and risk of infection that can come with a repeat biopsy. It turns out as many as 20% of men have prostate cancer, even if their first biopsy results are negative. Approximately 40% of men with a negative biopsy go on to receive a second biopsy. Many high-risk men fear sampling errors in their initial biopsy, which often leads to a high rate of follow-up procedures to merely confirm the absence of the disease.”
The study was published in the April 16, 2014, online edition of the Journal of Urology.
Related Links:
MDxHealth
Johns Hopkins University
Latest Pathology News
- Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
- AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
- New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







